CD44V6 in gastric carcinoma: A marker of tumor progression

Applied Immunohistochemistry and Molecular Morphology

Volumn 9, Issue 2, 2001, Pages 138-142

  Xin, Yan ^b   Grace, Antoinette ^b   Gallagher, Martina M ^b   Curran, Bernie T ^b   Leader, Mary B ^b   Kay, Elaine W ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b NONE

Author keywords

CD44V6; Gastric carcinoma; Prognosis

Indexed keywords

CD44V ANTIGEN; CD44V5 ANTIGEN; CD44V6 ANTIGEN; CELL SURFACE MARKER; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL INTERACTION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; SURVIVAL RATE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD44; DISEASE PROGRESSION; GASTRIC MUCOSA; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PROGNOSIS; RATS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0035009823     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200106000-00006     Document Type: Article

References (17)

1. Parkin DM, Stiernaward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 1984;62:163.
2. National Cancer Registry Ireland. Cancer in Ireland, Incidence and Mortality, 1996.
3. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89:1216-4.
4. Hofman M, Rudy W, Zoller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-7.
5. Rudy W, Hofman M, Albiez RS, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993;53:1262-8.
6. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
7. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993;341: 725-6.
8. Ham HJ, Ho LI, Chang JY, et al. Differential expression of the human metastasis adhesion molecule CD44 in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 1995;75: 1065-71.
9. Heider KH, Dammrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal-and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1995;15:1459-66.
10. Mirecka J, Mark D, Schauer A. Immunohistochemical localization of CD44 variants 5 and 6 in human gastric mucosa and gastric cancer. Anticancer Res 1995;15:1459-66.
11. Fox SB, Gatter KC, Jackson DG, et al. CD44 and cancer screening. Lancet 1993;342:548-9.
12. Müller W, Schneiders A, Heider KH, et al. Expression and prognostic value of the CD44 splicing variants V5 and V6 in gastric cancer. J Pathol 1997;183:222-7.
13. Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathologica Microbiologica Scandinavia 1965;64:31-49.
14. Man YG, Tavassoli FA. A simple epitope retrieval method without the use of microwave oven or enzyme digestion. Appl Immunohistochem 1996;4:139-141.
15. Mayer B, Jauch KW, Gunthert U, et al. De-novo expression of CD44 and surviral in gastric cancer. Lancet 1993;342:1019-22.
16. Hong RL, Lee WJ, Shun CT, et al. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 1995;52:334-9.
17. Washington K, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994;25:1043-9.